Timeline
Through innovative research and product development, InnoTherapy has established a distinguished portfolio of medical sealants while steadily expanding its position in the global market.
InnoTherapy continues to expand the scope of research and development of bio-therapeutics through strategic R&D collaboration programs that will drive further technological innovation.
Timeline
2021
InnoSEAL CE marking Approval
Relocation of Daejeon Research Center and branch
2020
Investment and strategic alliance with Finemedix
InnoSEAL approved in Israel, Argentina, and Malaysia
2019
InnoTherapy listed on KOSDAQ stock exchange
InnoSEAL Plus (absorbable hemostat) approval in Korea
EndoSil (absorbable hemostat) approval in Korea
InnoSEAL approved in Hong Kong, Pakistan
Investment from NVC
2018
InnoSEAL brand registration in Japan
InnoSEAL Plus pivotal clinical study completed
EndoSil pivotal clinical study completed
ISO 13485 certification
2017
InnoSEAL Plus first in human clinical trial completed
InnoSEAL Plus pivotal clinical study plan approved
EndoSil pivotal clinical study plan completed
Seoul manufacturing plant GMP certification
2016
InnoSEAL FDA 510(k) cleared
InnoSEAL Plus first-in-human clinical study plan approved
2015
InnoSEAL approval in Korea
Establishment of InnoTherapy America, Inc. in the U.S. (New Jersey)
GMP certification
Relocation of corporate office & Establishment of the Seoul Manufacturing Plant (Factory 2)
2014
NET certification for New Health Technology (Korean Ministry of Health and Welfare)
2013
Establishment of Daejeon branch
Establishment of Research Center & Completion of Cleanroom Facility
2010
Foundation of InnoTherapy Inc.